Why 1 #copywriter’s trek through #PharmaAdvertising shows the #talentcrisis facing the industry. We review #AdNomad http://wp.me/P23AlC-v0
Why 1 #copywriter’s trek through #PharmaAdvertising shows the #talentcrisis facing the industry. We review #AdNomad http://wp.me/P23AlC-v0
How a 600p #novel about #PharmaAdvertising reveals what’s wrong with #advertising today. We review #AdNomad http://wp.me/P23AlC-v0
How a 600p #novel about #PharmaAdvertising reveals what’s wrong with #advertising today. We review #AdNomad http://wp.me/P23AlC-v0
Gilead pays $4.3B for CymaBay, primarily for liver disease med—Pharma showed up for the big game — CSL’s ‘big’ post-heart attack drug fails in Phase III trial--http://bit.ly/w28kSd #gileadsciences #mergersandacquisitions #liverdisease #heartattack #clinicaltrials #superbowl #pharmaadvertising #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

Cafepharma